Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00992303Recruiting
Collecting tissue samples during radiation for people with cancer
This study collects tissue samples from people with cancer while they are getting radiation therapy. It also includes healthy participants, to help researchers compare samples and better understand cancer and treatment.
Dallas, TexasAges 18 years+ - NCT07481799RecruitingPhase 3
Targeted drug plus focused radiation for EGFR-positive cancer that has spread a little
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
Zhuhai, GuangdongAges 18–75 - NCT07483554RecruitingPhase 2
IBI343 combination therapy for advanced solid tumors
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07335770Enrolling by invitation
Heart MRI for diagnosing and managing heart masses
This trial uses cardiac MRI to better understand heart masses (tumors or clots) and guide treatment decisions. It may help determine what the mass is and how it affects your health.
Ages Any age - NCT07331532Recruiting
New pet scan to detect annexin a2 in lung tumors
This trial tests a new injection called 68Ga-PFA2 for PET/CT scans to find a protein called Annexin A2 in lung cancer tumors. It aims to see if this scan can better detect or characterize these tumors in patients who will have a biopsy or surgery soon.
Beijing, Beijing MunicipalityAges 18–80 - NCT04270591RecruitingPhase 1/Phase 2
Glumetinib for lung cancer with MET changes
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Louisville, KentuckyAges 18–80 - NCT07162779Enrolling by invitation
New PET scan for advanced prostate cancer patients
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
Wuxi, JiangsuAges 18–80 - NCT03707808RecruitingPhase 1/Phase 2
Study drugs into a tumor plus immune therapy for advanced cancer
This trial tests injecting an immune-boosting mixture directly into a skin or lymph node tumor, along with immune-checkpoint medicines given through the vein. It aims to help the body recognize and fight advanced cancers that can’t be fully removed by surgery.
Jette, BrabantAges 18 years+ - NCT06597721RecruitingPhase 1
ADCE-T02 for advanced solid tumors
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
Rogers, ArkansasAges 18 years+ - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Fayetteville, ArkansasAges 18–100 - NCT05872204RecruitingPhase 2
Abemaciclib plus letrozole for rare ER-positive ovarian cancer
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
Liège, LiègeAges 18 years+ - NCT07394374RecruitingPhase 1/Phase 2
CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
BeijingAges 18 years+ - NCT06298084RecruitingPhase 1/Phase 2
HER3-DXd for Advanced Breast Cancer After T-DXd
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
VillejuifAges 18 years+ - NCT06183762Recruiting
Real-world study of treatments for MET-mutation lung cancer
This study looks at how different treatments work for people with advanced lung cancer that has a MET mutation. It aims to understand real-world treatment patterns and outcomes to help guide future care.
Changsha, HunanAges 18 years+ - NCT06790264Recruiting
Special PET Scan for Breast Cancer - FAPi Imaging
This trial uses a special PET scan (68Ga-FAPi-46) to see how breast cancer interacts with nearby cells. It may help doctors understand your tumor better and guide treatment decisions, especially if you are planning surgery or chemotherapy before surgery.
Milan, ItalyAges 18 years+ - NCT06409013Recruiting
Dye-guided surgery for sarcoma removal
This study tests whether using a special dye during surgery helps doctors see and remove sarcoma tumors more completely. It may help improve the chances that no cancer is left behind.
Rochester, MinnesotaAges 18 years+ - NCT07172256RecruitingPhase 2
CUE-101 plus pembrolizumab for HPV+ throat cancer
This trial tests a new drug called CUE-101 combined with a standard immunotherapy (pembrolizumab) for people with HPV-16 positive head and neck cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT02530658Recruiting
Sequencing children’s tumor and normal tissue samples
This study collects children’s normal and tumor tissue (or blood-related normal samples) and reads their DNA/RNA to look at genetic information. It may help researchers understand cancer-related changes and improve future testing, even when the goal isn’t to treat you directly.
Memphis, TennesseeAges Any age - NCT03093909RecruitingPhase 1
Breathing treatment with gemcitabine for lung cancer spread
This early-stage trial studies an inhaled (aerosol) form of gemcitabine to treat solid tumors that have spread to the lungs. It aims to see whether this lung-focused treatment is safe and how well it might work when standard curative options are not available.
Houston, TexasAges 12–50 - NCT03334708Recruiting
Blood tests to study pancreas cancer and related conditions
This study checks whether blood-based tests can help learn about pancreas cancer and other pancreas conditions. It may help connect blood results with tumor biology to guide future care.
Middletown, New JerseyAges 18 years+ - NCT04181970Recruiting
Study of sarcoma care quality across Europe and Latin America
This observational study looks at information from people with sarcoma to understand how care is delivered across different centers. It does not test a new treatment, but may help improve future care and planning.
Buenos AiresAges 18–120 - NCT04265430RecruitingPhase 4
MRI scans to predict normal-tissue side effects after treatment
This trial uses repeated MRI scans to better predict which patients may develop painful jaw and mouth tissue problems after radiation and/or certain bone or blood-vessel medicines. It may help clinicians spot problems earlier and tailor follow-up care.
Houston, TexasAges 18 years+ - NCT04394052Recruiting
Imaging tests for suspected bone or soft-tissue tumors
This trial studies new imaging methods to better identify and stage (find how far it has spread) suspected bone or soft-tissue tumors. It may help your care team choose the most accurate next steps based on your scans.
Nancy, LorraineAges 18 years+
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,319 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.